No Record Found
Sector
PharmaceuticalsOpen
₹128.9Prev. Close
₹125.6Turnover(Lac.)
₹3.21Day's High
₹128.9Day's Low
₹125.552 Week's High
₹193.552 Week's Low
₹81Book Value
₹19.62Face Value
₹10Mkt Cap (₹ Cr.)
147.88P/E
251.2EPS
0.5Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | 
|---|---|---|---|---|
Equity Capital  | 11.49  | 11.49  | 11.49  | 11.63  | 
Preference Capital  | 0  | 0  | 0  | 0  | 
Reserves  | 11.06  | 9.67  | 7.87  | 1.12  | 
Net Worth  | 22.55  | 21.16  | 19.36  | 12.75  | 
Minority Interest  | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 | 
|---|---|---|---|---|
Revenue  | 2.37  | 7.67  | 5.8  | 5.27  | 
yoy growth (%)  | -69.1  | 32.33  | 9.92  | -26.96  | 
Raw materials  | -1.45  | -4.31  | -2.71  | -2.73  | 
As % of sales  | 61.45  | 56.13  | 46.85  | 51.85  | 
Employee costs  | -0.44  | -0.51  | -0.88  | -0.79  | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 | 
|---|---|---|---|---|
Profit before tax  | -1.25  | -0.47  | -2.47  | -0.96  | 
Depreciation  | -0.04  | -0.04  | -0.44  | -0.53  | 
Tax paid  | 0.12  | -1.53  | 0.07  | 0.29  | 
Working capital  | -1  | -2.28  | 3.43  | -4.45  | 
Other operating items  | 
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 | 
|---|---|---|---|---|
Growth matrix (%)  | ||||
Revenue growth  | -69.1  | 32.33  | 9.92  | -26.96  | 
Op profit growth  | -183.21  | -148.27  | -277.68  | -252.99  | 
EBIT growth  | -146.73  | -175.52  | -426.79  | -207.7  | 
Net profit growth  | -43.51  | -16.46  | 259.74  | -34.27  | 
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | 
|---|---|---|---|---|---|
Gross Sales  | 187.74  | 188.71  | 167.61  | 163.03  | 89.52  | 
Excise Duty  | 0  | 0  | 0  | 0  | 0  | 
Net Sales  | 187.74  | 188.71  | 167.61  | 163.03  | 89.52  | 
Other Operating Income  | 0  | 0  | 0  | 0  | 0  | 
Other Income  | 1.68  | 0.82  | 0.77  | 0.33  | 0.21  | 
Company Name  | LTP (₹)  | P/E  (%)  | Mkt.Cap  (₹Cr.)  | NP Qtr (₹Cr.)  | Div.Yield  (%)  | Sales Qtr  (₹.Cr)  | Book Value (₹)  | 
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA  | 1,707.25  | 82.24 | 4,09,626.46 | 753.53 | 0.94 | 5,566.68 | 101.44 | 
Divis Laboratories Ltd DIVISLAB  | 6,805.65  | 77.34 | 1,80,668.62 | 557 | 0.44 | 2,357 | 561.08 | 
Torrent Pharmaceuticals Ltd TORNTPHARM  | 3,628.15  | 61.77 | 1,22,787.57 | 551 | 0.17 | 2,567 | 224.34 | 
Cipla Ltd CIPLA  | 1,511.6  | 23.49 | 1,22,102.7 | 1,210.53 | 1.06 | 4,495.16 | 411.56 | 
Dr Reddys Laboratories Ltd DRREDDY  | 1,196.45  | 18.5 | 99,857.36 | 387.3 | 0.67 | 4,602.9 | 377.57 | 
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Ami M Shah
Independent Director
T V Anantharaman
Independent Director
Yogesh Varia
Independent Director
Harish S Panpalia
Director & Chief Executive Officer
Mihir Prakash Shah
Managing Director & CFO
Binoy Baiju Shah
Gala 114 Bldg No 8,
Jogani Ind Complex Chunabhatti,
Maharashtra - 400022
Tel: 91-022-6825 2525
Website: http://www.naxparlab.com
Email: compliance@naxparlab.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Parnax Lab Limited (Formerly Known as Krishna Deep Trade & Investment Ltd ) was incorporated in August, 1982. The Company changed the name from Krishna Deep Trade & Investment Ltd to Parnax Lab Limite...
Read More
Reports by Parnax Lab Ltd
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.